C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics Announces Chief Financial Officer Succession

05 Sep 2023 13:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

08 Aug 2023 04:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 Jul 2023 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

05 Jul 2023 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

20 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

30 May 2023 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

04 May 2023 04:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

19 Apr 2023 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

23 Feb 2023 04:00:02 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

08 Feb 2023 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

30 Jan 2023 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

09 Jan 2023 04:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 04:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

03 Nov 2022 04:00:02 By Nasdaq GlobeNewswire

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

29 Sep 2022 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

26 Sep 2022 04:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

04 Aug 2022 05:00:03 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors

02 Aug 2022 05:00:03 By Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

16 May 2022 05:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

05 May 2022 05:00:02 By Nasdaq GlobeNewswire